Einzeltreffer — DigiBib

The aim of this study was to assess the effect of Vertigoheel on central vestibular compensation and cognitive deficits in rats subjected to peripheral vestibular loss. Young adult male Long Evans rats were subjected to bilateral vestibular insults through irreversible sequential ototoxic destructions of the vestibular sensory organs. Vestibular syndrome characteristics were monitored at several time points over days and weeks following the sequential insults, using a combination of behavioral assessment paradigms allowing appreciation of patterns of change in static and dynamic deficits, together with spatial navigation, learning, and memory processes. Vertigoheel administered intraperitoneally significantly improved maximum body velocity and not moving time relative to its vehicle control on days 2 and 3 and on day 2, respectively, after unilateral vestibular lesion (UVL). It also significantly improved postural control relative to its vehicle 1 day after UVL. Conversely, Vertigoheel did not display any significant effect vs. vehicle on the severity of the syndrome, nor on the time course of other examined parameters, such as distance moved, mean body velocity, meander, and rearing. Spatial cognition testing using Y- and T-maze and eight-radial arm maze did not show any statistically significant difference between Vertigoheel and vehicle groups. However, Vertigoheel potentially enhanced the speed of learning in sham animals. Evaluating Vertigoheel's effect on thigmotaxis during the open-field video tracking test revealed no significant difference between Vertigoheel and its vehicle control groups suggesting that Vertigoheel does not seem to induce sedative or anxiolytic effects that could negatively affect vestibular and memory function. Present observations reveal that Vertigoheel improves central vestibular compensation following the unilateral peripheral vestibular loss as demonstrated by improvement of specific symptoms.

Competing Interests: Authors BH, RB, CB, and NC were employed by company Vertidiag. Authors AM, KW, and BS were employed by Heel GmbH. The authors declare that this study received funding from Heel GmbH. The funder had the following involvement: study design.

Titel:	Vertigoheel improves central vestibular compensation after unilateral peripheral vestibulopathy in rats.
Autor/in / Beteiligte Person:	Hatat, B ; Boularand, R ; Bringuier, C ; Chanut, N ; Besnard, S ; Mueller, AM ; Weyer, K ; Seilheimer, B ; Tighilet, B ; Chabbert, C
Link:	Full Text Finder (Volltext)
Zeitschrift:	Frontiers in neurology, Jg. 13 (2022-09-23), S. 969047
Veröffentlichung:	[Lausanne : Frontiers Research Foundation, 2010]-, 2022
Medientyp:	academicJournal
ISSN:	1664-2295 (print)
DOI:	10.3389/fneur.2022.969047
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Front Neurol] 2022 Sep 23; Vol. 13, pp. 969047. <i>Date of Electronic Publication: </i>2022 Sep 23 (<i>Print Publication: </i>2022). References: Front Neurol. 2020 Jun 05;11:505. (PMID: 32582016) ; Brain Struct Funct. 2019 Mar;224(2):699-711. (PMID: 30470894) ; Hippocampus. 2012 Apr;22(4):814-26. (PMID: 21538662) ; Behav Brain Res. 2008 Nov 3;193(1):55-62. (PMID: 18547657) ; Prog Neurobiol. 2019 Mar;174:28-35. (PMID: 30658127) ; Ann N Y Acad Sci. 2015 Apr;1343:49-57. (PMID: 25766597) ; J Neurosci. 2016 Jun 8;36(23):6199-212. (PMID: 27277799) ; J Physiol. 2006 Jun 15;573(Pt 3):723-39. (PMID: 16613878) ; Biomedicines. 2022 Aug 27;10(9):. (PMID: 36140199) ; Microvasc Res. 2005 Jan;69(1-2):10-6. (PMID: 15797255) ; Hippocampus. 2016 Dec;26(12):1509-1514. (PMID: 27569857) ; Behav Brain Res. 1992 Mar 15;47(1):13-22. (PMID: 1571099) ; Ear Nose Throat J. 2006 Jan;85(1):25-35. (PMID: 16509240) ; Front Neurol. 2020 May 29;11:470. (PMID: 32547480) ; Eur J Pharmacol. 2015 Dec 15;769:342-9. (PMID: 26607469) ; J Vestib Res. 2013;23(3):177-86. (PMID: 24177349) ; Neuroscience. 2012 Aug 30;218:161-9. (PMID: 22633950) ; Hippocampus. 2014 May;24(5):591-7. (PMID: 24464878) ; Psychol Bull. 1976 May;83(3):482-504. (PMID: 17582919) ; Drugs. 1995 Nov;50(5):777-91. (PMID: 8586026) ; Behav Neurosci. 2008 Apr;122(2):448-59. (PMID: 18410183) ; Dis Model Mech. 2019 Jul 15;12(7):. (PMID: 31213478) ; J Vestib Res. 1995 Jan-Feb;5(1):53-66. (PMID: 7711948) ; Brain. 2005 Nov;128(Pt 11):2732-41. (PMID: 16141283) ; Arzneimittelforschung. 2005;55(1):23-9. (PMID: 15727161) ; J Neurosci Methods. 2018 Jan 01;293:128-135. (PMID: 28911857) ; Pharmacol Biochem Behav. 1994 Dec;49(4):859-69. (PMID: 7886099) ; J Altern Complement Med. 2005 Feb;11(1):155-60. (PMID: 15750375) ; Behav Brain Res. 2008 Jan 10;186(1):1-11. (PMID: 17822783) ; Curr Opin Neurol. 2000 Feb;13(1):27-30. (PMID: 10719646) ; Prog Neurobiol. 1995 Jun;46(2-3):97-129. (PMID: 7568917) ; Ann N Y Acad Sci. 2009 May;1164:134-9. (PMID: 19645891) ; J Vestib Res. 2017;27(2-3):89-101. (PMID: 29064826) ; Front Mol Neurosci. 2020 Aug 11;13:140. (PMID: 32848601) ; Ann N Y Acad Sci. 2009 May;1164:127-33. (PMID: 19645890) ; Front Neurol. 2018 Jun 11;9:431. (PMID: 29942281) ; Otolaryngol Head Neck Surg. 1998 Jul;119(1):34-42. (PMID: 9674512) ; Toxicol Appl Pharmacol. 2012 Jan 1;258(1):61-71. (PMID: 22023963) ; J Neurosci. 2003 Jul 23;23(16):6490-8. (PMID: 12878690) ; Behav Brain Res. 2012 Feb 1;227(1):150-8. (PMID: 22101174) ; Neurosci Lett. 2012 Jul 26;522(1):57-61. (PMID: 22705908) ; Eur J Pharmacol. 2007 Jul 30;568(1-3):149-63. (PMID: 17573072) ; J Neurol. 2016 Apr;263 Suppl 1:S54-64. (PMID: 27083885) ; Arch Otolaryngol Head Neck Surg. 1998 Aug;124(8):879-85. (PMID: 9708713) ; Restor Neurol Neurosci. 2010;28(1):19-35. (PMID: 20086280) ; Multisens Res. 2015;28(5-6):461-85. (PMID: 26595952) ; Physiol Behav. 1990 Jul;48(1):27-30. (PMID: 2236275) ; Neuroimage. 2021 Feb 1;226:117588. (PMID: 33249212) ; J Neurosci Methods. 2017 May 01;283:83-91. (PMID: 28390798) ; Prog Neurobiol. 2021 Jan;196:101899. (PMID: 32858093) ; PLoS One. 2017 Nov 7;12(11):e0187472. (PMID: 29112981) ; J Psychopharmacol. 2014 Jul;28(7):655-64. (PMID: 24346808) ; Handb Clin Neurol. 2016;137:207-18. (PMID: 27638072) ; Neurosci Lett. 2018 Sep 14;683:43-47. (PMID: 29936267) ; Ann N Y Acad Sci. 2009 May;1164:268-78. (PMID: 19645911) ; Clin Hemorheol Microcirc. 2010;46(1):23-35. (PMID: 20852360) ; J Neurophysiol. 1995 Nov;74(5):2087-99. (PMID: 8592199) ; J Neuroinflammation. 2010 Dec 09;7:91. (PMID: 21143912) ; Neuropharmacology. 1998;37(3):323-30. (PMID: 9681930) ; Acta Otolaryngol Suppl. 1993;509:1-19. (PMID: 8285044) Contributed Indexing: Keywords: Vertigoheel; central vestibular compensation; multitarget medication; natural drug; sequential bilateral lesion; spatial cognitive deficits; unilateral vestibular lesion; vestibular disorders Entry Date(s): Date Created: 20221010 Latest Revision: 20221011 Update Code: 20231215 PubMed Central ID: PMC9541623

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Vertigoheel improves central vestibular compensation after unilateral peripheral vestibulopathy in rats.